8-K: Hims & Hers Q3 Revenue Soars 49%, Narrows 2025 Outlook

Hims & Hers Health, Inc. reported robust third-quarter 2025 financial results, with revenue up 49% year-over-year and a narrowed full-year guidance, driven by subscriber growth and strategic expansion.

Summary

• Q3 2025 revenue reached $599.0 million, a 49% increase year-over-year.
• Net income was $15.8 million, down from $75.6 million in Q3 2024, primarily due to a $60.8 million tax benefit in the prior year.
• Adjusted EBITDA grew 53% year-over-year to $78.4 million.
• Subscribers increased 21% year-over-year to nearly 2.5 million.
• Monthly Online Revenue per Average Subscriber rose 19% year-over-year to $80.
• Full-year 2025 revenue guidance narrowed to $2.335 billion to $2.355 billion.
• Full-year 2025 Adjusted EBITDA guidance narrowed to $307 million to $317 million.

Sentiment

Score: 8

Explanation: The filing presents strong financial growth across key metrics like revenue, Adjusted EBITDA, and subscribers. Strategic initiatives in new specialties, vertical integration, and international expansion are well-articulated and show significant future potential. While GAAP net income decreased due to a prior-year tax benefit and gross margin slightly compressed, the overall operational performance and forward-looking statements are highly positive, indicating robust business momentum and confidence in future trajectory.

Positives

• Strong revenue growth of 49% year-over-year in Q3 2025, reaching $599.0 million.
• Adjusted EBITDA increased 53% year-over-year to $78.4 million in Q3 2025.
• Subscriber base grew 21% year-over-year to nearly 2.5 million.
• Monthly Online Revenue per Average Subscriber increased 19% year-over-year to $80.
• Net cash provided by operating activities surged 74% year-over-year to $148.7 million in Q3 2025.
• Narrowed full-year 2025 revenue and Adjusted EBITDA guidance, indicating increased confidence in financial performance.
• Successful expansion into new specialties like testosterone and menopause care, showing strong product-market fit and cross-selling opportunities.
• Significant progress in verticalizing 503A operations, aiming to fulfill the majority of compounded GLP-1 orders internally by end of 2026, which is expected to lower pricing and expand access.
• Reduced prices across personalized GLP-1 treatment plans by up to 20%, enhancing accessibility.
• International expansion with the acquisition of ZAVA Global and launch in Spain, with plans for Canada.
• Strategic investment in GRAIL for early detection and screening innovations.
• Share repurchase authorization of up to $100 million, with $10 million repurchased in Q3 2025, signaling management's belief in intrinsic value.

Negatives

• GAAP Net income decreased significantly to $15.8 million in Q3 2025 from $75.6 million in Q3 2024, primarily due to a non-recurring $60.8 million tax benefit in the prior year.
• Gross margin declined to 74% in Q3 2025 from 79% in Q3 2024, attributed to shorter shipping cadences for weight loss offerings and increased fulfillment costs.
• Technology and development expenses increased from 5% to 7% of revenue year-over-year in Q3 2025.
• General and administrative expenses increased from 11% to 13% of revenue year-over-year in Q3 2025, partly due to Zava integration and new leadership hiring.

Risks

• Forward-looking statements are subject to various factors, and actual results may differ materially from expectations.
• Discussions with Novo Nordisk regarding Wegovy availability are ongoing, with no definitive agreement executed, and there is a possibility no agreement may ever be executed or terms may differ from current anticipation.
• The FDA's resolution of the semaglutide shortage and the conclusion of its enforcement discretion period for 503B outsourcing facilities have constrained and are expected to continue to constrain the ability to provide access to compounded semaglutide on the platform.
• The company's ability to comply with extensive, complex, and evolving legal and regulatory requirements, including healthcare, privacy, and consumer protection laws.

Future Outlook

Hims & Hers anticipates continued strong growth, projecting Q4 2025 revenue between $605 million and $625 million and Adjusted EBITDA of $55 million to $65 million. For the full year 2025, revenue is expected to be $2.335 billion to $2.355 billion, with Adjusted EBITDA of $307 million to $317 million. The company plans to expand into new specialties like testosterone and menopause care, launch comprehensive lab testing and a longevity specialty in 2026, and continue international expansion in markets such as Canada, Brazil, the UK, Germany, and Australia. Strategic partnerships, including active discussions with Novo Nordisk for Wegovy, are also a key focus.

Management Comments

• "Our vision of helping tens of millions of people around the world access best-in-class, personalized care, from the comfort of their own home is more real than ever. We're building a platform that gets more personal, more proactive, and resonates with more people as we scale." Andrew Dudum, co-founder and CEO.
• "We delivered another quarter of strong, profitable growth as our model continues to scale and deepen its impact. In the third quarter, revenue grew 49% and Adjusted EBITDA grew 53% year over year, driven by execution against our strategy to broaden access to personalized care that can increasingly serve customers across a wider range of needs." Yemi Okupe, CFO.
• "The opportunities to accelerate our trajectory are materializing quicker than expected, and we're leaning in." Andrew Dudum, co-founder and CEO.
• "We are confident that with continued execution, we can lead industry efforts to provide broader access to these life-changing medications." Andrew Dudum, co-founder and CEO.

Industry Context

The announcement reflects the ongoing expansion and maturation of the telehealth and direct-to-consumer health and wellness industry. Hims & Hers is actively diversifying beyond its initial offerings into broader men's and women's health, including weight management (GLP-1s), testosterone therapy, and menopause care. The focus on personalized care, vertical integration (compounding infrastructure), diagnostic capabilities, and international expansion positions the company to capitalize on increasing consumer demand for accessible and tailored healthcare solutions, aligning with broader trends of digital health adoption and preventative care.

Comparison to Industry Standards

• The company aims to establish a "new gold standard" in compounding infrastructure, particularly for GLP-1s, by sourcing APIs from FDA-registered facilities and Green List suppliers.
• The company's growth in subscribers and revenue, coupled with its expansion into new specialties like testosterone and menopause, indicates a strong competitive position within the direct-to-consumer health market.
• The investment in GRAIL for early detection and screening reflects an interest in advanced diagnostics, a growing area in healthcare, though specific comparable companies or projects are not detailed in the filing.
• The acquisition of ZAVA Global and planned expansion into Canada and other international markets positions Hims & Hers against global telehealth providers, aiming to become the "largest global consumer health platform."

Stakeholder Impact

• Shareholders: Positive impact from strong revenue and Adjusted EBITDA growth, narrowed positive guidance, and share repurchase program.
• Customers: Enhanced access to personalized care through new specialties (testosterone, menopause), reduced prices for GLP-1 treatments, and planned diagnostic/longevity offerings.
• Employees: Continued investment in staffing, fulfillment, processing, engineering, and product talent.
• Suppliers: Emphasis on sourcing active pharmaceutical ingredients (APIs) from FDA-registered facilities and Green List suppliers, indicating a focus on quality and regulatory compliance.

Next Steps

• Host a conference call to review Q3 2025 results on November 3, 2025.
• Launch comprehensive lab testing capabilities in the near future (before year-end).
• Launch a longevity specialty in 2026.
• Expand oral testosterone offering with a branded, FDA-approved therapy through Marius Pharmaceuticals in 2026.
• Continue efforts to verticalize 503A operations, aiming to fulfill the majority of compounded GLP-1 orders internally by the end of 2026.
• Prepare to launch the platform in Canada in the near future, anticipating generic semaglutide availability in 2026.
• Evaluate deeper investments in key international markets including Brazil, the U.K., Germany, and Australia.
• Continue exploring opportunities to collaborate with partners across the healthcare ecosystem.
• Ongoing active discussions with Novo Nordisk to make Wegovy injections and oral Wegovy (when FDA approved) available through the platform.

Key Dates

Recommendation

The company demonstrates exceptional growth across key operational metrics, including a 49% year-over-year revenue increase and a 53% rise in Adjusted EBITDA. Subscriber growth remains robust, and the strategic expansion into new, high-demand specialties like weight management, testosterone, and menopause care, coupled with significant investments in vertical integration and international markets, positions Hims & Hers for sustained long-term growth. The narrowed full-year guidance reflects management's confidence, and while GAAP net income was impacted by a non-recurring tax benefit in the prior year, the underlying operational performance is strong. The active discussions with Novo Nordisk for Wegovy further highlight potential for market leadership. These factors collectively suggest a compelling investment opportunity.

Keywords

Hims & Hers, HIMS, Q3 2025 Earnings, Telehealth, Digital Health, Personalized Care, Weight Management, GLP-1, Men's Health, Women's Health, Testosterone Therapy, Menopause Care, Diagnostics, International Expansion, Healthcare Platform, Subscription Health, Compounding Pharmacy